Summit Therapeutics Inc. (SMMT)
undefined
undefined%
At close: undefined
17.86
-0.17%
After-hours Dec 13, 2024, 07:09 PM EST

Company Description

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America.

It conducts clinical programs focusing on Clostridioides difficile infection (CDI).

The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI.

It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae.

The company was founded in 2003 and is based in Cambridge, Massachusetts.

Summit Therapeutics Inc.
Summit Therapeutics Inc. logo
Country United States
IPO Date Mar 5, 2015
Industry Biotechnology
Sector Healthcare
Employees 105
CEO Robert W. Duggan

Contact Details

Address:
One Broadway
Cambridge, Massachusetts
United States
Website https://www.summittxinc.com

Stock Details

Ticker Symbol SMMT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001599298
CUSIP Number 86627T108
ISIN Number US86627T1088
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. Mahkam Zanganeh D.D.S., M.B.A. Co-Chief Executive Officer, President & Director
Robert W. Duggan Co-Chief Executive Officer & Executive Chairman
Manmeet Singh Soni CPA Chief Operating Officer, Chief Financial Officer & Director
Bhaskar Anand Chief Accounting Officer & Head of Finance
Dave Gancarz Chief Business & Strategy Officer
Divya Chari Head of Global Clinical Operations
Dr. Betty Y. Chang Ph.D. Head of Research, Oncology & Inflammation
Dr. Fong Clow Chief Biometrics Officer
Prof. Dame Kay Davies DBE, FRS CBE Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
Shelley D. Spray Chief Education & Brand Officer

Latest SEC Filings

Date Type Title
Oct 30, 2024 10-Q Quarterly Report
Oct 30, 2024 8-K Current Report
Oct 15, 2024 4 Filing
Oct 03, 2024 4 Filing
Sep 26, 2024 D Filing
Sep 19, 2024 S-3ASR Automatic shelf registration statement of securiti...
Sep 13, 2024 4 Filing
Sep 13, 2024 4 Filing
Sep 13, 2024 SC 13D/A [Amend] Filing
Sep 13, 2024 4 Filing